Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 3/2012

01-03-2012 | Letter to the Editor

Lenalidomide is active for extramedullary disease in refractory multiple myeloma

Authors: Tomonori Nakazato, Ai Mihara, Chisako Ito, Yukinari Sanada, Yoshinobu Aisa

Published in: Annals of Hematology | Issue 3/2012

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M (2010) Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1,003 consecutive patients. Ann Oncol 21:325–330PubMedCrossRef
2.
Blade J, Perales M, Rosinol L et al (2001) Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas. Br J Haematol 113:422–424PubMedCrossRef
3.
Rosinol L, Cibeira MT, Blade J et al (2004) Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica 89:832–836PubMed
4.
Laura R, Cibeira MT, Uriburu C et al (2006) Bortezomib: an effective agent in extramedullary disease in multiple myeloma. Eur J Haematol 76:405–408PubMedCrossRef
5.
Patriarca F, Prosdocimo S, Tomadini V et al (2005) Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation. Haematologica 90:278–279PubMed
6.
Sher T, Miller KC, Lee K, Chanan-Khan A (2009) Remission induction with lenalidomide alone in a patient with previously untreated plasmablastic myeloma: a case report. Clin Lymphoma Myeloma 9:328–330PubMedCrossRef
Metadata
Title
Lenalidomide is active for extramedullary disease in refractory multiple myeloma
Authors
Tomonori Nakazato
Ai Mihara
Chisako Ito
Yukinari Sanada
Yoshinobu Aisa
Publication date
01-03-2012
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 3/2012
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-011-1272-6

Other articles of this Issue 3/2012

Annals of Hematology 3/2012 Go to the issue

Letter to the Editor

Association between acute lymphoblastic leukemia (ALL) and der(8;9)(q10;q10): a novel case of double der(8;9) in Ph+ adult B cell ALL

Letter to the Editor

Mimicry of hydroxyurea-induced leg ulcer by distal vena saphena parva insufficiency

Original Article

Circulating IL-17 levels during the peri-transplant period as a predictor for early leukemia relapse after myeloablative allogeneic stem cell transplantation

Original Article

Lymphopenia following the completion of first-line therapy predicts early relapse in patients with diffuse large B cell lymphoma

Original Article

In vitro vessel-forming capacity of endothelial progenitor cells in high glucose conditions

Original Article

Allogeneic bone marrow transplantation compared to peripheral blood stem cell transplantation for the treatment of hematologic malignancies: a meta-analysis based on time-to-event data from randomized controlled trials
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits